Abstract 1262
Background
Osimertinib is an oral, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). In both EGFR-TKI sensitizing and EGFR T790M resistance mutations in advanced non-small-cell lung cancer (NSCLC), osimertinib has shown to improve survival. Nevertheless, cardiac toxicities remain a safety concern. We undertook a systematic review and meta-analysis of randomized controlled trials (RCT) to determine the incidence of cardiac toxicities.
Methods
MEDLINE, EMBASE databases and meeting abstracts from inception through March 2018 were queried. Phase III RCTs that mentioned cardiac failure (CF), decrease in ejection fraction (EF) and ECG QT prolongation as adverse effects were incorporated in the analysis. Mantel-Haenszel (MH) method was used to calculate the estimated pooled risk ratio (RR) and absolute risk difference (RD) with 95% confidence interval (CI). A fixed effects model was applied.
Results
971 patients with advanced NSCLC from two phase III RCTs were included. Studies compared osimertinib vs carboplatin/cisplatin + pemetrexed and osimertinib vs gefitinib/erlotinib. The I2 statistic for heterogeneity was 0, and the heterogeneity X2 (Cochran’s Q) was 1 (P = 0.787), suggesting homogeneity among RCTs. The CF incidence was 21 (3.763%) in the osimertinib group vs 6 (1.453%) in control group. The RR for CF was 2.719 (95% CI: 1.094 – 6.755, P = 0.031) and RD was 0.026 (95% CI: 0.006 – 0.046, P = 0.012). The decrease in EF was noted in 16 (2.867%) in study arm vs 5 (1.211%) in control arm. The RR for decrease in EF was 2.502 (95% CI: 0.927 –6.753, P = 0.070) and RD was 0.019 (95% CI: - 0.001 – 0.037, P = 0.037). The QT prolongation was reported in 35 (6.272%) vs 12 (2.906%) in control group with the RR of 2.623 (95% CI: 1.374 –5.007, P = 0.003) and RD of 0.04 (95% CI: - 0.017 – 0.071, P = 0.002).
Conclusions
Chemotherapy-induced cardiotoxicity, a major cause of morbidity and mortality, is one of the most feared complications and affects patients’ quality of life and adds financial burden. Our study showed that osimertinib notably increased the risk of cardiac toxicities with a RR of 2.71 for CF and 2.62 for QT prolongation. Prompt monitoring and early intervention is warranted.
Clinical trial identification
Legal entity responsible for the study
Kyaw Zin Thein/ Texas Tech University Health Sciences Center.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract